Lipocine Inc. Sets Sales Agent Fee Cap of Up to 3.0%

What Happened
Lipocine Inc. announced in an 8-K (filed Sept. 11, 2026) that on September 8, 2026 it and A.G.P./Alliance Global Partners (the Sales Agent) agreed the Sales Agent’s fee on sales made under the Sales Agreement dated April 26, 2024 will be up to 3.0%, subject to adjustment by the Company and the Sales Agent.

Key Details

• Agreement date on the fee change: September 8, 2026; 8-K filed September 11, 2026.
• Sales Agent: A.G.P./Alliance Global Partners.
• Fee cap: up to 3.0% on sales under the Sales Agreement dated April 26, 2024.
• Fee is "subject to adjustment" by Lipocine and the Sales Agent; no other changes to the Sales Agreement were disclosed.

Why It Matters
This establishes the percentage fee Lipocine will pay the Sales Agent for securities sold under the existing Sales Agreement. If Lipocine uses that Sales Agreement for future offerings or sales, the fee charged will be up to 3.0% (unless later adjusted), which determines the portion of gross proceeds that goes to the Sales Agent. The filing does not disclose other material terms or any immediate financing transactions.